Mark Makhinson, PharmD, MBA

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.

Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.

Factor XIa inhibitors emerge as safer stroke prevention, cutting harmful clots without excess bleeding—see which oral and IV drugs reach phase 3.

Learn how anticoagulants, antiplatelets, and atrial appendage closure prevent repeat ischemic stroke—and why early follow-up boosts adherence.

Learn how tailored meds, diet, exercise, and cholesterol control help prevent repeat ischemic stroke—while balancing bleeding risk and adherence.

Experts reveal gaps in stroke detection, follow‑up and prevention, plus a simple “MATH” guide to hemorrhagic causes and blood pressure goals.

Discover the stroke care team—from primary care to rehab—plus proven prevention steps and the high stakes of recurrent stroke.

Stroke subtypes vary widely, but prevention is clear: control blood pressure, diabetes, cholesterol, exercise, quit smoking, and cut disability costs.

Panelists examine the societal impact of stroke by outlining its prevalence, underlying pathophysiology, key modifiable risk factors, and the substantial clinical, economic, and long-term disability burden it places on patients and the healthcare system.

Panelists explore stroke classification and clinical presentation, highlighting key differences between ischemic and hemorrhagic strokes, the TOAST system for subtype identification, and the importance of understanding underlying causes to guide diagnosis and long-term management.